E
Valeo Pharma Inc.
VPH.TO
TSX
E
Sell
5/2/2023Downgrade
Valeo Pharma Inc. (VPH.TO) was downgraded to E+ from D- on 5/2/2023 due to a noticeable decline in the volatility index, total return index and solvency index. Debt to equity increased from -3.46 to -2.54, and the quick ratio declined from 1.82 to 1.47.
Valeo Pharma Inc. (VPH.TO) was downgraded to E+ from D- on 5/2/2023 due to a noticeable decline in the volatility index, total return index and solvency index. Debt to equity increased from -3.46 to -2.54, and the quick ratio declined from 1.82 to 1.47.
D
Sell
3/14/2023Downgrade
Valeo Pharma Inc. (VPH.TO) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
Valeo Pharma Inc. (VPH.TO) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
Valeo Pharma Inc. (VPH.TO) was upgraded to D from D- on 02/23/2023.
Valeo Pharma Inc. (VPH.TO) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
Valeo Pharma Inc. (VPH.TO) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the solvency index and total return index. Debt to equity increased from -8.2 to -3.46, and the quick ratio declined from 1.94 to 1.82.
Valeo Pharma Inc. (VPH.TO) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the solvency index and total return index. Debt to equity increased from -8.2 to -3.46, and the quick ratio declined from 1.94 to 1.82.
D
Sell
5/16/2022Upgraded
Valeo Pharma Inc. (VPH.TO) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Valeo Pharma Inc. (VPH.TO) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Valeo Pharma Inc. (VPH.TO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
Valeo Pharma Inc. (VPH.TO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
Valeo Pharma Inc. (VPH.TO) was upgraded to D from E+ on 05/04/2022.
Valeo Pharma Inc. (VPH.TO) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Valeo Pharma Inc. (VPH.TO) was downgraded to E+ from D on 05/01/2022.
Valeo Pharma Inc. (VPH.TO) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
Valeo Pharma Inc. (VPH.TO) was upgraded to D from E+ on 04/21/2022.
Valeo Pharma Inc. (VPH.TO) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Valeo Pharma Inc. (VPH.TO) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index, volatility index and valuation index.
Valeo Pharma Inc. (VPH.TO) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index, volatility index and valuation index.
D
Sell
11/23/2021Upgraded
Valeo Pharma Inc. (VPH) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
Valeo Pharma Inc. (VPH) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
Valeo Pharma Inc. (VPH) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index and valuation index. Operating cash flow declined 253.35% from -$1.27M to -$4.47M, and earnings per share declined from -$0.0226 to -$0.0342.
Valeo Pharma Inc. (VPH) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index and valuation index. Operating cash flow declined 253.35% from -$1.27M to -$4.47M, and earnings per share declined from -$0.0226 to -$0.0342.
D
Sell
5/1/2020Upgraded
Valeo Pharma Inc. (VPH) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index, volatility index and growth index. Total revenue increased 44.6% from $884.8 to $1.28M, EBIT increased 26.49% from -$1.15M to -$844.8, and earnings per share increased from -$0.0186 to -$0.0149.
Valeo Pharma Inc. (VPH) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index, volatility index and growth index. Total revenue increased 44.6% from $884.8 to $1.28M, EBIT increased 26.49% from -$1.15M to -$844.8, and earnings per share increased from -$0.0186 to -$0.0149.
D
Sell
11/5/2019Upgraded
Valeo Pharma Inc. (VPH) was upgraded to D- from E on 11/5/2019 due to an increase in the solvency index and growth index. The quick ratio increased from 0.13 to 0.36, total revenue increased 158.25% from $758.3 to $1.96M, and earnings per share increased from -$0.0179 to -$0.004.
Valeo Pharma Inc. (VPH) was upgraded to D- from E on 11/5/2019 due to an increase in the solvency index and growth index. The quick ratio increased from 0.13 to 0.36, total revenue increased 158.25% from $758.3 to $1.96M, and earnings per share increased from -$0.0179 to -$0.004.
E
Sell
8/13/2019Upgraded
Valeo Pharma Inc. (VPH) was upgraded to E from E- on 8/13/2019 due to an increase in the valuation index.
Valeo Pharma Inc. (VPH) was upgraded to E from E- on 8/13/2019 due to an increase in the valuation index.
E
Sell
7/29/2019Downgrade
Valeo Pharma Inc. (VPH) was downgraded to E- from E on 7/29/2019 due to a large decline in the volatility index and total return index.
Valeo Pharma Inc. (VPH) was downgraded to E- from E on 7/29/2019 due to a large decline in the volatility index and total return index.
E
Sell
7/12/2019Upgraded
Valeo Pharma Inc. (VPH) was upgraded to E from E- on 7/12/2019 due to a large increase in the volatility index, efficiency index and valuation index.
Valeo Pharma Inc. (VPH) was upgraded to E from E- on 7/12/2019 due to a large increase in the volatility index, efficiency index and valuation index.
E
Sell
6/13/2019Downgrade
Valeo Pharma Inc. (VPH) was downgraded to E- from E on 6/13/2019 due to a major decline in the volatility index.
Valeo Pharma Inc. (VPH) was downgraded to E- from E on 6/13/2019 due to a major decline in the volatility index.
E
Sell
5/15/2019None
Valeo Pharma Inc. (VPH.TO) was downgraded to E from U on 05/15/2019.
Valeo Pharma Inc. (VPH.TO) was downgraded to E from U on 05/15/2019.
